Frequently asked questions
Common questions about retatrutide, answered from the trial record
Plain-language answers sourced from published Phase 1, Phase 2, and review literature.
What does retatrutide do?
Retatrutide activates three hormone receptors simultaneously — GLP-1R (appetite and insulin), GIPR (fat metabolism and insulin), and GCGR (energy expenditure and liver fat breakdown) — producing appetite suppression, blood-sugar control, and increased resting calorie burn in a single molecule. In Phase 2 trials, this combination produced up to 24.2% average body-weight loss over 48 weeks in participants with obesity [1].
How does retatrutide work?
Retatrutide is a triple agonist: it binds to and activates three class-B G-protein-coupled receptors (GPCRs) — GLP-1R, GIPR, and GCGR — at once. GLP-1R and GIPR activation suppresses appetite and stimulates glucose-dependent insulin secretion; GCGR activation increases energy expenditure and hepatic lipid breakdown. Cryo-EM structural studies confirmed simultaneous triple-receptor engagement at atomic resolution [3]. The retatrutide mechanism of action page covers the pharmacology in full.
How to reconstitute retatrutide?
There is no published reconstitution protocol for retatrutide. In clinical trials it is supplied as a pre-formulated investigational product. Research-labeled gray-market vials are unverified for identity and purity; the FDA has issued warning letters to vendors. This site does not provide reconstitution instructions. Any research handling of a peptide requires analytical identity confirmation and sterility testing — neither of which gray-market supply chains provide.
Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA or any regulatory body as of 2026. It is an investigational compound in Phase 3 clinical trials (Eli Lilly's TRIUMPH program). All published efficacy and safety data come from controlled trials, not from an approved label. The closest approved drugs — semaglutide and tirzepatide — are distinct compounds with their own approved indications; retatrutide's regulatory status is pending Phase 3 completion and review [6][9].
When will retatrutide be available?
No regulatory approval timeline has been publicly confirmed by Eli Lilly. Phase 3 TRIUMPH trials are ongoing as of 2026. After Phase 3 data are collected and reviewed, a new drug application (NDA) or equivalent would need to be submitted and reviewed — a process that typically takes at least a year after trial completion. The compound is not commercially available today in any approved form [9][10].
How to take retatrutide?
In clinical trials, retatrutide was administered as a subcutaneous injection — under the skin of the abdomen, thigh, or upper arm — once weekly. Trials used a dose-escalation approach starting at lower doses to manage GI tolerability before reaching target doses. Retatrutide is not an approved product; there is no prescriber guide, patient label, or authorized administration protocol outside clinical-trial conditions [1][4].
How long does retatrutide take to work?
The Phase 1b trial detected placebo-adjusted weight loss of −8.96 kg over 12 weeks at the highest dose group, suggesting meaningful efficacy within the first three months [4]. The Phase 2 obesity trial showed that the largest weight-loss differences from placebo accumulated progressively through 48 weeks. Community reports describe noticeable changes in appetite within the first weeks, but these are anecdotal accounts from research-use settings, not clinical findings [1].
Is retatrutide better than tirzepatide?
No head-to-head human trial has been published. In a 2026 preclinical comparison in MC4R knockout mice, tirzepatide produced the greatest body-weight reduction (31.6%), followed by retatrutide (24.1%) and semaglutide (19.7%) [12]. This preclinical finding cannot be directly applied to human rankings. A dedicated Phase 3 active-comparator trial of retatrutide versus tirzepatide is underway in the TRIUMPH program; results are pending.
How much retatrutide per week?
In Phase 2 obesity trials, once-weekly doses of 1, 4, 8, and 12 mg were studied; 12 mg produced the largest weight reduction (−24.2%) [1]. In Phase 1b, a stepped escalation reaching a top dose of 12 mg was tested [4]. These are study-design facts — doses administered in specific, monitored clinical trials. They are not a dosing recommendation. Retatrutide is an unapproved investigational compound; no approved dose exists.
How to mix retatrutide with bacteriostatic water?
There is no published protocol for mixing retatrutide with bacteriostatic water. In clinical trials, retatrutide is supplied as a pre-formulated, sterility-tested investigational product — not as a lyophilized powder for patient reconstitution. Gray-market vials require confirmation of identity before any research handling. This site does not provide reconstitution, mixing, or preparation instructions.
How to switch from tirzepatide to retatrutide?
No published clinical guidance exists on transitioning between these compounds because retatrutide is not an approved drug. In the ongoing Phase 3 active-comparator trial, the transition protocol will be defined by the study design, not by current published evidence. Questions about switching GLP-1-class medications require medical oversight; this site does not offer clinical guidance [12].
Is retatrutide a GLP-3?
No. "GLP-3" is a popular but incorrect shorthand. There is no GLP-3 receptor — GLP-3 is a peptide fragment that is not a functional incretin and has no confirmed receptor. Retatrutide is correctly described as a triple agonist at GIP, GLP-1, and glucagon receptors (GIP + GLP-1 + GCGR). The misnomer "GLP-3" circulates in community discussions but does not reflect the pharmacology [3][7].
Is retatrutide available?
Retatrutide is not commercially available. The only setting in which a person can receive authentic retatrutide is enrollment in an active clinical trial. Gray-market research-labeled material exists but is unverified for identity, purity, and sterility. The FDA issued over 50 warning letters to retatrutide vendors in 2025 [6].
What is retatrutide used for?
In clinical trials, retatrutide has been studied for obesity, type 2 diabetes, and MASLD (metabolic fatty liver disease). Ongoing Phase 3 trials also include cardiovascular outcomes and chronic kidney disease. It is not an approved drug and therefore has no approved indication. A 2025 review characterizes it as a step-change in obesity pharmacotherapy based on Phase 1/2 data [6].
What receptors does retatrutide target?
Retatrutide simultaneously targets three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR) — all class-B G-protein-coupled receptors involved in incretin and metabolic hormone signaling. Cryo-EM structural studies confirmed binding at all three at atomic resolution. Relative potency versus the endogenous hormones: 8.9× at GIPR, 0.3× at GCGR, 0.4× at GLP-1R [3].
Is retatrutide legal?
As an unapproved drug, retatrutide does not have a regulatory schedule like a controlled substance, but distributing it as a drug without approval violates the Federal Food, Drug, and Cosmetic Act. The FDA issued over 50 warning letters to retatrutide vendors in 2025 on this basis. GLP-1/GIP/glucagon agonists are not specifically prohibited on the current WADA Prohibited List, but athletes should consult the current list, as the status of investigational agents can change [6].
How often do you take retatrutide?
Clinical trials used once-weekly subcutaneous administration, supported by retatrutide's approximately 6-day half-life [4]. No daily or biweekly dosing has been published for humans. This is a study-design fact; retatrutide has no approved dosing interval because it is not an approved drug.
What is the half-life of retatrutide?
Approximately 6 days, established in the Phase 1b trial by Urva et al. (Lancet, 2022) [4]. This extended half-life is achieved by acylating the peptide with a C20 fatty-diacid chain that promotes binding to serum albumin, slowing clearance. The 6-day half-life directly enables once-weekly dosing — the regimen used in all subsequent Phase 2 trials.
How to store retatrutide?
No approved storage guidelines exist for retatrutide because it is not an approved product. In clinical trials, the investigational product is handled under GMP conditions with defined cold-chain specifications set by the sponsor. Gray-market lyophilized preparations carry no validated stability data. General principles applicable to research peptides (refrigeration of lyophilized powder, cold-chain maintenance, avoidance of repeated freeze-thaw) are not a substitute for validated stability data specific to this compound.
Is retatrutide the same as Ozempic?
No. Retatrutide and semaglutide (the compound marketed as Ozempic in one indication) are distinct molecules with different pharmacological profiles. Semaglutide is a GLP-1 receptor agonist only — it targets one receptor. Retatrutide is a triple agonist targeting GLP-1R, GIPR, and GCGR simultaneously. Semaglutide is an approved drug with labeled indications; retatrutide is an investigational compound not approved by any regulator. In a preclinical head-to-head comparison in MC4R knockout mice, semaglutide, tirzepatide, and retatrutide all improved metabolic parameters, with distinct effect magnitudes [12].
Is retatrutide better than semaglutide?
No published head-to-head human trial compares retatrutide directly to semaglutide. Indirect comparisons from separate trials suggest retatrutide's Phase 2 weight-loss results (−24.2% at 48 weeks) exceed semaglutide's Phase 3 results in comparable obesity populations, but these figures come from different trials with different populations and endpoints. A 2026 preclinical study in MC4R knockout mice measured 19.7% weight loss with semaglutide versus 24.1% with retatrutide — a directional difference in one animal model that cannot be generalized to humans [12].
What company makes retatrutide?
Retatrutide (LY3437943) is being developed by Eli Lilly and Company. Lilly's clinical development program is branded TRIUMPH (Triple Hormone Receptor Agonist for Metabolic Progress and Health). Lilly holds the IND (Investigational New Drug application) and is sponsoring all registered Phase 3 trials. The discovery paper (Coskun et al., Cell Metabolism, 2022) includes Lilly researchers as authors [7].